



**GROUP OF
BIOTECHNOLOGY AND
PHARMACEUTICAL
INDUSTRIES**

STRUCTURE




WHO WE ARE?

32	Enterprises (+16 abroad, include 7 JV)
65	Facilities
80	Production lines
21	Scientific facilities
+20 000	Workers
	+17000 Professionals, technicians and operators
	1265 MSc
	278 PhD

Group that integrates the biotechnological and high technology research centers, the industrial production of medicines, equipment and medical devices in Cuba for the prevention and treatment of diseases that affect human and veterinary health, as well as commercialization.

SCIENCE FOR A HEALTHY LIFE

ENTERPRISES



R&D, PRODUCTION AND COMMERCIALIZATION



- Generics



- Biosimilar products



- Innovative products

- Natural products



- Equipment and Devices



- Blood derived products

- Products derived from Placenta




- Agricultural Products

RELEVANT FIGURES

±1000	PRODUCTS
+400	PROJECTS
165	OBJECTS OF INVENTION
+2600	PATENTS
+780	MARKETING APPROVALS IN
+50	COUNTRIES
+40	COUNTRIES OF EXPORTS

MARKETING APPROVALS



664 Latin America
21 Europe

28 Africa
70 Asia

MAIN BUSINESS LINES



Commercial
products



R&D
projects




Foreign
investment
proposals



R&D PROJECTS



R&D
projects



Access link:
https://www.biocubafarma.cu/doc/c_proyectos_negocios_en.pdf

MEDICAL RESEARCH SPECIALTIES



Oncology

Immunology



Cardiology

Ophthalmology



Cicatrization

Nutrition



Neurology

Agro-veterinary



Dermatology

Other





CUBAN
VACCINES

ANTI
COVID-19



COMMERCIAL PRODUCTS




Commercial
products



Access link:
https://www.biocubafarma.cu/doc/c_productos_en.pdf

COVID-19 PRODUCTS



Biomodulina-T®

- Natural biological drug extracted from bovine thymus



HeberFERON®

- Combination of recombinant human interferon alpha 2b with recombinant human gamma interferon in a single vial.



Nasalferon

- Pharmaceutical composition of recombinant human IFN-alpha-2b for nasal administration.



Itolizumab

- An anti-CD6 humanized monoclonal



PrevengHo Vir

- Homeopathic product to prevent influenza, dengue or emergent viral diseases.



Jusvinza®

- A HSP60-derived immunoregulatory peptide.

FOREIGN INVESTMENT PROPOSALS



Foreign investment proposals



Title	Cuban company
Manufacturing facility of monoclonal antibodies and recombinant proteins from mammalian cells.	CIMAB S.A
Generic medicines manufacturing in semisolid oral presentation.	Pharmaceutic Laboratory MedSol
Manufacturing facility of Blood derived products.	Serums and Blood Derived Products Facility (Laboratorios AICA+)
Biotechnological and pharmaceutical logistics Operator Center.	Medicine marketing and distribution company (EMCOMED)
Manufacturing facility for cytostatic products.	Laboratorios AICA+
Manufacturing and commercialization facility of Human Placenta derived products.	Placental Histotherapy Center, HISPLACEN
International Economic Association to complete and start-up a manufacturing facility of semi-solid medicines.	Pharmaceutic Laboratory “Roberto Escudero”
International Economic Association Contract for manufacturing and commercialization of the Classic Swine Fever Vaccine “Porvac”.	Center for Genetic Engineering and Biotechnology (CIGB)

POTENTIAL COMMON INTERESTS

- ❖ Alliances for the clinical development and commercialization of Cuban biotechnology products in Germany and Europe.
- ❖ Research Agreements and academic collaboration for the development of innovative products.
- ❖ Incorporation of Joint Venture Companies in both countries for the development and manufacturing of biopharmaceutical products.
- ❖ Access to Risk Capital to accelerate the development of innovative products.
- ❖ To set up strategic alliances with Germany suppliers to purchase raw materials and devices for Cuban bio-pharmaceutical industry.



THANKS!

April 14th, 2021

Danneris Martínez Domínguez

Business Development Department

Office: (+53) 72745114

danneris@oc.biocubafarma.cu